A landmark agreement between the UK Medical Research Council (MRC) and AstraZeneca will allow researchers access to a number of high potential compounds.

Through MRC funding, UK academia will conduct studies on 22 compounds to help understand the secrets behind a range of diseases.

As part of the collaboration, the MRC is also inviting research proposals from across the academic community to use the compounds in new areas.

The MRC will then judge and select the best scientific proposals, and award up to £10 million to fund the research across a broad range of human diseases.

Sir John Savill, chief executive of the Medical Research Council, said the collaboration marks a new era in medical discovery, open innovation and public-private collaboration.

David Willetts, minister for Universities and Science, echoed the statement saying the landmark agreement will keep the UK at the forefront of biomedical research, as well as drive growth and innovation in the UK’s life sciences industry.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The rights to intellectual property generated using the compounds are based on the project, but the MRC believes they will be similar to those currently used in academically-led research.

AstraZeneca will retain rights over the chemical composition of the compounds.